AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

AbbVie Earnings Call Signals Strong Growth Ahead - TipRanks

Drug approval Earnings report Guidance raised AI-generated analysis

๐Ÿ“ˆ AbbVie delivered adjusted Q3 earnings of $3.82, beating the guidance midpoint by $0.07.

๐Ÿ’ฐ Net revenue reached $17.4 billion, representing a 10.5% operational increase and exceeding expectations by $200 million.

๐Ÿš€ The company raised full-year adjusted EPS guidance to $13.95-$13.99 and lifted the revenue forecast to $67.8 billion.

๐Ÿ’Š Skyrizi sales surged 22.9% to nearly $5.8 billion, capturing significant market share in psoriasis and IBD.

๐Ÿงฌ Rinvoq commercialization expanded with sales climbing 24.3% to $2.7 billion across immunology indications.

๐Ÿง  Neuroscience revenue grew 19.5% operationally to nearly $3.4 billion, led by Vraylar and Ubrelvy.

๐Ÿ’‰ AbbVie completed the acquisition of Apogee Therapeutics to gain assets in dermatology and respiratory disease.

๐Ÿ”ฌ The Phase III EPCORE DLBCL-2 study showed Epkinly plus R-CHOP cut disease progression risk by 51%.

๐Ÿ“‰ Humira revenue declined 30.6% operationally to $683 million due to continued biosimilar competition.

๐Ÿ’ธ Imbruvica sales dropped 26.1% due to competitive share losses and IRA-related pricing pressure.

๐ŸŽจ Aesthetics revenue fell 1.8% operationally as Juvรฉderm sales decreased 11.8% amid market weakness.

๐Ÿ’ต AbbVie generated approximately $14 billion in free cash flow during the first nine months of the year.

๐Ÿ“… The company will raise its quarterly dividend by 5.2% to $1.82 per share beginning in February 2027.

๐Ÿ”ฎ Management expects Skyrizi and Rinvoq to produce combined growth of $6 billion in 2026.

โš–๏ธ AbbVie remains focused on reaching a net leverage ratio of 2x within two to three years.

Bullish Signals
  • AbbVie reported adjusted Q3 earnings of $3.82, beating the guidance midpoint by $0.07.
  • Net revenue reached $17.4 billion, up 10.5% operationally and $200 million above expectations.
  • The company raised full-year adjusted EPS guidance to $13.95-$13.99 and lifted the revenue forecast to $67.8 billion.
  • Skyrizi sales rose 22.9% to nearly $5.8 billion, capturing roughly one in two new psoriasis patients.
  • Rinvoq sales climbed 24.3% to $2.7 billion, with commercialization expanding into vitiligo and alopecia areata.
  • Neuroscience revenue grew 19.5% operationally to nearly $3.4 billion, driven by Vraylar and Ubrelvy growth.
  • AbbVie completed the acquisition of Apogee Therapeutics, gaining assets in dermatology and respiratory disease.
  • The Phase III EPCORE DLBCL-2 study found Epkinly plus R-CHOP cut disease progression risk by 51%.
  • AbbVie generated approximately $14 billion in free cash flow during the first nine months of the year.
  • The company will raise its quarterly dividend by 5.2% to $1.82 per share beginning in February 2027.
Risk Factors
  • Humira revenue fell 30.6% operationally to $683 million as biosimilar competition continued to erode sales.
  • Imbruvica sales dropped 26.1% due to competitive share losses and IRA-related pricing pressure, lowering full-year guidance to $2.1 billion.
  • Aesthetics revenue declined 1.8% operationally with Juvรฉderm sales down 11.8% amid continued weakness in dermal-filler markets.
  • Management cited economic uncertainty and lower consumer confidence as factors contributing to the decline in aesthetics revenue.
  • The IRA price for Vraylar will begin in 2027, representing a future pressure on the franchise's financial performance.
  • AbbVie is working with the FDA on outstanding issues connected with the complete response letter for Boey regarding manufacturing and chemistry matters.
Full Analysis
AbbVie reported a strongly positive third quarter with adjusted earnings per share of $3.82, beating guidance by $0.07, and net revenue reaching $17.4 billion, up 10.5% operationally. The company significantly raised its full-year outlook, increasing the adjusted EPS midpoint to $13.95-$13.99 and lifting the revenue forecast by $200 million to approximately $67.8 billion. This performance was driven by double-digit growth across nine key products, particularly in immunology and neuroscience segments. The company's post-Humira growth strategy is gaining traction as Skyrizi sales rose 22.9% to nearly $5.8 billion and Rinvoq climbed 24.3% to $2.7 billion. AbbVie also highlighted robust performance in its oncology portfolio, where Venclexta sales increased 10.7%, helping to offset expected declines in Imbruvica due to competitive pressures and IRA-related pricing changes. The business generated approximately $14 billion in free cash flow during the first nine months. Looking ahead, AbbVie raised its quarterly dividend by 5.2% to $1.82 per share starting in February 2027 and expects combined growth of $6 billion from Skyrizi and Rinvoq in 2026. While the company faces headwinds from biosimilar erosion on Humira, which fell 30.6%, and weakness in the aesthetics market with Juvรฉderm sales down 11.8%, management remains confident in delivering top-tier growth in 2027 supported by a productive pipeline and new indications for existing drugs.